Company Profile For Allergan, Inc.

Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company is engaged in discovering, developing and commercializing specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological and other specialty markets in more than 100 countries globally. In January 2007, the Company completed the acquisition of Groupe Corneal Laboratoires (Corneal). In October 2007, the Company completed the acquisition of Esprit Pharma Holding Company, Inc. (Esprit). In July 2008, the Company acquired the Aczone (dapsone) gel 5% from QLT USA, Inc. (QLT), a wholly owned subsidiary of QLT Inc. The Company operates in two business segments: specialty pharmaceuticals and medical devices.

BRIEF: For the nine months ended 30 September 2009, Allergan Inc.'s revenues decreased 2% to $3.28B. Net income decreased 4% to $399.8M. Revenues reflect a decrease in product net sales and lower other revenues. Net income also reflects increased amortization of aquired intangible assets, higher restructuring charges, decreased interest income, higher unreaslized loss on derivative instruments and higher other, net.